SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe E. who wrote (2273)10/11/1997 11:35:00 AM
From: H. Bradley Toland, Jr.   of 6136
 
Joe:

My understanding is that Agouron's approach when they created Thymitaq was they were trying to engineer a better version of a widely used ( $800 million + in sales) chemotherapy drug--5 FU--which has awful side effects but does kill cancer cells. I've not seen any of the Phase 2 information but my expectation is that if Thymitaq is as effective, or better than, 5 FU with less severe side effects then the chance of getting an FDA approval would be fairly good. Roche liked what they saw well enough to parter with AGPH on good terms so that adds some comfort.

Also, Some people have commented about the MMP inhibitor which is in phase 1 with Roche as a partner. British Biotech also one which is advanced clinical trials and has caused considerable excitement. My understanding is Agouron believes their MMP inhibitor may be significantly different than British Biotech's.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News